Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?

Journal of Comparative Neurology

Volumn 522, Issue 12, 2014, Pages 2802-2816

  Buttery, Philip C ^a   Barker, Roger A ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Dopamine; Embryonic; Gene therapy; Growth factor; Pharmaco genetics; Pluripotent

Indexed keywords

AMANTADINE; APOMORPHINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGENEIC VENTRAL MESENCEPHALON STEM CELL TRANSPLANTATION; BRAIN DAMAGE; BRAIN DEPTH STIMULATION; BRAIN REGION; GENE THERAPY; GENETIC REGULATION; HUMAN; INTERMETHOD COMPARISON; NERVE CELL DEGENERATION; OPTOGENETICS; PARKINSON DISEASE; PHARMACOGENETICS; REVIEW; STEM CELL TRANSPLANTATION; SUBTHALAMIC NUCLEUS; TREATMENT RESPONSE; TRIPLE GENE THERAPY; HISTORY; TRENDS;

HISTORY, 21ST CENTURY; HUMANS; PARKINSON DISEASE; STEM CELL TRANSPLANTATION;

EID: 84911994237     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.23577     Document Type: Review

References (154)

1. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G. 2007. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 22:1145-1149.
2. Arjona V, Minguez-Castellanos A, Montoro RJ, Ortega A, Escamilla F, Toledo-Aral JJ, Pardal R, Méndez-Ferrer S, Martín JM, Pérez M, Katati MJ, Valencia E, García T, López-Barneo J. 2003. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 53:321-328-discussion 328-330.
3. Aston-Jones G, Deisseroth K. 2013. Recent advances in optogenetics and pharmacogenetics. Brain Res 1511:1-5.
4. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. 2013. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136:374-384.
5. Aybek S, Gronchi-Perrin A, Berney A, Chiuvé SC, Villemure JG, Burkhard PR, Vingerhoets FJG. 2007. Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease. Mov Disord 22:974-981.
6. Azzouz M, Martin-Rendon E, Barber RD, Mitrophanous KA, Carter EE, Rohll JB, Kingsman SM, Kingsman AJ, Mazarakis ND. 2002. Multicistronic lentiviral vectormediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 22:10302-10312.
7. Backlund EO, Granberg PO, Hamberger B, Knutsson E, Mårtensson A, Sedvall G, Seiger A, Olson L. 1985. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 62:169-173.
8. Ballanger B, Jahanshahi M, Broussolle E, Thobois S. 2009. PET functional imaging of deep brain stimulation in movement disorders and psychiatry. J Cereb Blood Flow Metab 29:1743-1754.
9. Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J, Herscovitch P, Carson RE, Eckelman W, Reutter B, Cunningham J. 2006. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14:564-570.
10. Barker RA. 2006. Continuing trials of GDNF in Parkinson's disease. Lancet Neurol 5:285-286.
11. Barker RA, Barrett J, Mason SL, Björklund A. 2013. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol 12:84-91.
12. Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, Johnson EM Jr, Kordower JH, Herzog CD. 2011. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis 44:38-52.
13. Bartus RT, Baumann TL, Brown L, Kruegel BR, Ostrove JM, Herzog CD. 2013. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiol Aging 34:35-61.
14. Benabid A-L, Chabardes S, Mitrofanis J, Pollak P. 2009. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 8:67-81.
15. Björklund A, Stenevi U, Dunnett SB, Iversen SD. 1981. Functional reactivation of the deafferented neostriatum by nigral transplants. Nature 289:497-499.
16. Boertien T, Zrinzo L, Kahan J, Jahanshahi M, Hariz M, Mancini L, Limousin P, Foltynie T. 2011. Functional imaging of subthalamic nucleus deep brain stimulation in Parkinson's disease. Mov Disord 26:1835-1843.
17. Brederlau A, Correia AS, Anisimov SV, Elmi M, Paul G, Roybon L, Morizane A, Bergquist F, Riebe I, Nannmark U, Carta M, Hanse E, Takahashi J, Sasai Y, Funa K, Brundin P, Eriksson PS, Li J-Y. 2006. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 24:1433-1440.
18. Brundin P, Nilsson OG, Strecker RE, Lindvall O, Astedt B, Björklund A. 1986. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp Brain Res 65:235-240.
19. Brundin P, Barker RA, Parmar M. 2010. Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res 184:265-294.
20. Burn DJ, Barker RA. 2013. Mild cognitive impairment in Parkinson's disease: millstone or milestone? Pract Neurol 13:68-69.
21. Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L. 2010. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev 19:1017-1023.
22. Caiazzo M, Dell'Anno MT, Dvoretskova E, Lazarevic D, Taverna S, Leo D, Sotnikova TD, Menegon A, Roncaglia P, Colciago G, Russo G, Carninci P, Pezzoli G, Gainetdinov RR, Gustincich S, Dityatev A, Broccoli A. 2011. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476:224-227.
23. Calabresi P, Picconi B, Parnetti L, Di Filippo M. 2006. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 5:974-983.
24. Calabresi P, Picconi B, Tozzi A, Difilippo M. 2007. Dopaminemediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30:211-219.
25. Canavero S, Paolotti R. 2000. Extradural motor cortex stimulation for advanced Parkinson's disease: case report. Mov Disord 15:169-171.
26. Ceregene. Press release 2013
27. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. 2009. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27:275-280.
28. Chaudhuri KR, Healy DG, Schapira AHV, National Institute for Clinical Excellence. 2006. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5:235-245.
29. Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X. 2008. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28:425-433.
30. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ. 2009. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73:1662-1669.
31. Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. 2006. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 494:495-514.
32. Clarke DJ, Brundin P, Strecker RE, Nilsson OG, Björklund A, Lindvall O. 1988. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry. Exp Brain Res 73:115-126.
33. Creedon DJ, Tansey MG, Baloh RH, Osborne PA, Lampe PA, Fahrner TJ, Heuckeroth RO, Milbrandt J, Johnson EM. 1997. Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proc Natl Acad Sci U S A 94:7018-7023.
34. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Björklund A. 2012. a-Synuclein-induced downregulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 4:163ra156.
35. Desouza R, Moro E, Lang A, Schapira A. 2013. Timing of deep brain stimulation in Parkinson's disease: a need for reappraisal? Ann Neurol 73:565-575.
36. Desplats P, Lee H-J, Bae E-J, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee S-J. 2009. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106:13010-13015.
37. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider G-H, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J, Section GPSGN. 2006. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355:896-908.
38. Deuschl G, Schüpbach M, Knudsen K, Pinsker MO, Cornu P, Rau J, Agid Y, Schade-Brittinger C. 2013. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 19:56-61.
39. Dezawa M, Kanno H, Hoshino M, Cho H, Matsumoto N, Itokazu Y, Tajima N, Yamada H, Sawada H, Ishikawa H, Mimura T, Kitada M, Suzuki Y, Ide C. 2004. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 113:1701-1710.
40. Drinkut A, Tereshchenko Y, Schulz JB, Bähr M, Kügler S. 2012. Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery. Mol Ther 20:534-543.
41. El-Andaloussi S, Lee Y, Lakhal-Littleton S, Li J, Seow Y, Gardiner C, Alvarez-Erviti L, Sargent IL, Wood MJA. 2012. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc 7:2112-2126.
42. Evans JR, Mason SL, Barker RA. 2012. Current status of clinical trials of neural transplantation in Parkinson's disease. Prog Brain Res 200:169-198.
43. Farrell MS, Roth BL. 2013. Pharmacosynthetics: reimagining the pharmacogenetic approach. Brain Res 1511:6-20.
44. Fasano S, Bezard E, D'Antoni A, Francardo V, Indrigo M, Qin L, Doveró S, Cerovic M, Cenci MA, Brambilla R. 2010. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A 107:21824-21829.
45. Ferraye MU, Debû B, Fraix V, Goetz L, Ardouin C, Yelnik J, Henry-Lagrange C, Seigneuret E, Piallat B, Krack P, Le Bas JF, Benabid AL, Chabardès S, Pollak P. 2010. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain 133:205-214.
46. Fisher LJ, Young SJ, Tepper JM, Groves PM, Gage FH. 1991. Electrophysiological characteristics of cells within mesencephalon suspension grafts. Neuroscience 40:109-122.
47. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-719.
48. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA. 1996. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255.
49. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-595.
50. Grace AA. 2000. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev 31:330-341.
51. Grace AA. 2008. Physiology of the normal and dopaminedepleted basal ganglia: insights into levodopa pharmacotherapy. Mov Disord 23(suppl 3):S560-569.
52. Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. 2009. Optical deconstruction of parkinsonian neural circuitry. Science 324:354-359.
53. Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, Widner H, Brundin P, Rothwell JC, Odin P, Wenning GK, Morrish P, Gustavii B, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. 1999. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 122:1121-1132.
54. Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, Yow A, Soldner F, Hockemeyer D, Hallett PJ, Osborn T, Jaenisch R, Isacson O. 2010. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A 107:15921-15926.
55. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. 2008. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 23:837-844.
56. Holgado AJN, Terry JR, Bogacz R. 2010. Conditions for the generation of beta oscillations in the subthalamic nucleus-globus pallidus network. J Neurosci 30:12340-12352.
57. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR. 2009. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468-1474.
58. Horger BA, Nishimura MC, Armanini MP, Wang LC, Poulsen KT, Rosenblad C, Kirik D, Moffat B, Simmons L, Johnson E, Milbrandt J, Rosenthal A, Björklund A, Vandlen RA, Hynes MA, Phillips HS. 1998. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18:4929-4937.
59. Hu B-Y, Weick JP, Yu J, Ma L-X, Zhang X-Q, Thomson JA, Zhang S-C. 2010. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A 107:4335-4340.
60. Itakura T, Uematsu Y, Nakao N, Nakai E, Nakai K. 1997. Transplantation of autologous sympathetic ganglion into the brain with Parkinson's disease. Long-term follow-up of 35 cases. Stereotact Funct Neurosurg 69:112-115.
61. Jarraya B, Boulet S, Ralph GS, Jan C, Bonvento G, Azzouz M, Miskin JE, Shin M, Delzescaux T, Drouot X, Hérard A-S, Day DM, Brouillet E, Kingsman SM, Hantraye P, Mitrophanous KA, Mazarakis ND, Palfi S. 2009. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1:2ra4.
62. Jenner P. 2008. Preventing and controlling dyskinesia in Parkinson's disease: a view of current knowledge and future opportunities. Mov Disord 23:S585-S598.
63. Kadkhodaei B, Alvarsson A, Schintu N, Ramsköld D, Volakakis N, Joodmardi E, Yoshitake T, Kehr J, Decressac M, Björklund A, Sandberg R, Svenningsson P, Perlmann T. 2013. Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc Natl Acad Sci U S A 110:2360-2365.
64. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. 2009. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458:771-775.
65. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ. 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369:2097-2105.
66. Karachi C, Grabli D, Bernard FA, Tandé D, Wattiez N, Belaid H, Bardinet E, Prigent A, Nothacker H-P, Hunot S, Hartmann A, Lehericy S, Hirsch EC, François C. 2010. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 120:2745-2754.
67. Kim J-H, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky N, Lee S-H, Nguyen J, Sanchez-Pernaute R, Bankiewicz K, McKay R. 2002. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418:50-56.
68. Kiskinis E, Eggan K. 2010. Progress toward the clinical application of patient-specific pluripotent stem cells. J Clin Invest 120:51-59.
69. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Déglon N, Aebischer P. 2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-773.
70. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. 2008. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14:504-506.
71. Kravitz AV, Freeze BS, Parker PRL, Kay K, Thwin MT, Deisseroth K, Kreitzer AC. 2010. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466:622-626.
72. Kriks S, Shim J-W, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L. 2011. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480:547-551.
73. Kuan W-L, Poole E, Fletcher M, Karniely S, Tyers P, Wills M, Barker RA, Sinclair JH. 2012. A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med 209:1-10.
74. Kühn AA, Doyle L, Pogosyan A, Yarrow K, Kupsch A, Schneider G-H, Hariz MI, Trottenberg T, Brown P. 2006. Modulation of beta oscillations in the subthalamic area during motor imagery in Parkinson's disease. Brain 129:695-706.
75. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VGF, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M. 2006. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-466.
76. Langston JW. 2006. The parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann Neurol 59:591-596.
77. Lee Y, EL Andaloussi S, Wood MJA. 2012. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 21:R125-R134.
78. Lees AJ, Hardy J, Revesz T. 2009. Parkinson's disease. Lancet 373:2055-2066.
79. Lelos MJ, Dowd E, Dunnett SB. 2012. Nigral grafts in animal models of Parkinson's disease. Is recovery beyond motor function possible? Prog Brain Res 200:113-142.
80. Leroi I, McDonald K, Pantula H, Harbishettar V. 2012. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol 25:208-214.
81. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A. 2011. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, shamsurgery controlled, randomised trial. Lancet Neurol 10:309-319.
82. Lhommée E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A, Kistner A, Fraix V, Xie J, Aya Kombo M, Chabardes S, Seigneuret E, Benabid A-L, Mertens P, Polo G, Carnicella S, Quesada J-L, Bosson J-L, Broussolle E, Pollak P, Krack P. 2012. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 135:1463-1477.
83. Li J-Y, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. 2008. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14:501-503.
84. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Broussolle E, Perret JE, Benabid AL. 1995a. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord 10:672-674.
85. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL. 1995b. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345:91-95.
86. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. 1993. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
87. Lin TP, Carbon M, Tang C, Mogilner AY, Sterio D, Beric A, Dhawan V, Eidelberg D. 2008. Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain 131:1373-1380.
88. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD. 1990. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247:574-577.
89. Lindvall O, Sawle G, Widner H, Rothwell JC, Björklund A, Brooks D, Brundin P, Frackowiak R, Marsden CD, Odin P. 1994. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 35:172-180.
90. Little S, Brown P. 2012. What brain signals are suitable for feedback control of deep brain stimulation in Parkinson's disease? Ann N Y Acad Sci 1265:9-24.
91. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM-Y. 2009. Exogenous alphasynuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 106:20051-20056.
92. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, During MJ. 2002. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298:425-429.
93. Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, Freed C, Dhawan V, Eidelberg D. 2010. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)FFDOPA PET outcomes. J Nucl Med 51:7-15.
94. Madrazo I, Drucker-Colin R, Díaz V, Martínez-Mata J, Torres C, Becerril JJ. 1987. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N Engl J Med 316:831-834.
95. Marks WJ, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT. 2008. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7:400-408.
96. Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW. 2010. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 9:1164-1172.
97. Marsden CD, Parkes JD. 1976. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1:292-296.
98. Mazzone P, Lozano A, Stanzione P, Galati S, Scarnati E, Peppe A, Stefani A. 2005. Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson's disease. Neuroreport 16:1877-1881.
99. Mazzulli JR, Xu Y-H, Sun Y, Knight AL, Mclean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. 2011. Gaucher disease glucocerebrosidase and a-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37-52.
100. Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O. 2008. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 14:507-509.
101. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, Kaplan PL, Forsayeth J, Aminoff MJ, Bankiewicz KS. 2012. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 23:377-381.
102. Moro E, Schwalb JM, Piboolnurak P, Poon Y-YW, Hamani C, Hung SW, Arenovich T, Lang AE, Chen R, Lozano AM. 2011. Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. Brain 134:2096-2105.
103. Nair SG, Strand NS, Neumaier JF. 2013. DREADDing the lateral habenula: a review of methodological approaches for studying lateral habenula function. Brain Res 1511:93-101.
104. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AHV, Halliday G. 2010. Missing pieces in the Parkinson's disease puzzle. Nat Med 16:653-661.
105. Okita K, Hong H, Takahashi K, Yamanaka S. 2010. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc 5:418-428.
106. Olanow CW. 2008. Levodopa/dopamine replacement strategies in Parkinson's disease-future directions. Mov Disord 23(suppl 3):S613-622.
107. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. 2003. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403-414.
108. Olanow CW, Kordower JH, Lang AE, Obeso JA. 2009. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol 66:591-596.
109. Ostrosky-Solís F, Quintanar L, Madrazo I, Drucker-Colin R, Franco-Bourland R, Leon-Meza V. 1988. Neuropsychological effects of brain autograft of adrenal medullary tissue for the treatment of Parkinson's disease. Neurology 38:1442-1450.
110. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA. 2014. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet. [Epub ahead of print].
111. Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ, Citri A, Sebastiano V, Marro S, Südhof TC, Wernig M. 2012. Induction of human neuronal cells by defined transcription factors. Nature 476:220-223.
112. Parish CL, Castelo-Branco G, Rawal N, Tønnesen J, Sorensen AT, Saltó C, Kokaia M, Lindvall O, Arenas E. 2008. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest 118:149-160.
113. Parkinson's UK. 2012. Parkinson's prevalence in the United Kingdom 2009. London: Parkinson'sUK. p 1-13.
114. Piccini P, Brooks DJ, Björklund A, Gunn RN, Grasby PM, Rimoldi O, Brundin P, Hagell P, Rehncrona S, Widner H, Lindvall O. 1999. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2:1137-1140.
115. Piccini P, Lindvall O, Björklund A, Brundin P, Hagell P, Ceravolo R, Oertel W, Quinn N, Samuel M, Rehncrona S, Widner H, Brooks DJ. 2000. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 48:689-695.
116. Plaha P, Gill SS. 2005. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. Neuroreport 16:1883-1887.
117. Politis M, Lindvall O. 2012. Clinical application of stem cell therapy in Parkinson's disease. BMC Med 10:1.
118. Politis M. 2010. Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? BMC Med 8:80.
119. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Björklund A, Lindvall O, Piccini P. 2012. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Science Transl Med 4:128-141.
120. Pollak P, Benabid AL, Limousin P, Krack P. 1996. Treatment of Parkinson's disease. New surgical treatment strategies. Eur Neurol 36:400-404.
121. Quinn NP. 1998. Classification of fluctuations in patients with Parkinson's disease. Neurology 51(2 suppl 2):S25-29.
122. Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, Fénelon G, Gény C, Ricolfi F, Frouin V. 1995. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 38:580-588.
123. Rosin B, Slovik M, Mitelman R, Rivlin-Etzion M, Haber SN, Israel Z, Vaadia E, Bergman H. 2011. Closed-loop deep brain stimulation is superior in ameliorating parkinsonism. Neuron 72:370-384.
124. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. 2006. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 12:1259-1268.
125. Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, Zhang Z, Gerhardt GA, Gash DM. 2006. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 202:497-505.
126. Sass KJ, Buchanan CP, Westerveld M, Marek KL, Farhi A, Robbins RJ, Naftolin F, Vollmer TL, Leranth C, Roth RH. 1995. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. Arch Neurol 52:680-686.
127. Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, Fischman AJ, Thomas C, Feldman RG, Kassissieh S, Raineri R, Manhart C, Penney D, Fink JS, Isacson O. 2000. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54:1042-1050.
128. Simuni T, Sethi K. 2009. Nonmotor manifestations of Parkinson's disease. Ann Neurol 64(suppl 2):S65-S80.
129. Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, Walton A, Wagner R, Young AB. 2007. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 106:614-620.
130. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R. 2009. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136:964-977.
131. Solis O, Limón DI, Flores-Hernández J, Flores G. 2007. Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson's disease. Synapse 61:450-458.
132. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. 2008. Induced pluripotent stem cells generated without viral integration. Science 322:945-949.
133. Swistowski A, Peng J, Liu Q, Mali P, Rao MS, Cheng L, Zeng X. 2010. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells 28:1893-1904.
134. Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y, Fukuda H, Okamoto Y, Koyanagi M, Ideguchi M, Hayashi H, Imazato T, Kawasaki H, Suemori H, Omachi S, Iida H, Itoh N, Nakatsuji N, Sasai Y, Hashimoto N. 2005. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 115:102-109.
135. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676.
136. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872.
137. Taylor H, Barua N, Bienemann A, Wyatt M, Castrique E, Foster R, Luz M, Fibiger C, Mohr E, Gill S. 2013. Clearance and Toxicity of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor r-metHu GDNF Following Acute Convection-Enhanced Delivery into the Striatum. PLoS ONE 8:e56186.
138. Temel Y, Visser-Vandewalle V, Kaplan S, Kozan R, Daemen MARC, Blokland A, Schmitz C, Steinbusch HWM. 2006. Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res 1120:100-105.
139. Thompson L, Björklund A. 2012. Survival, differentiation, and connectivity of ventral mesencephalic dopamine neurons following transplantation. Prog Brain Res 200:61-95.
140. Tofaris GK. 2012. Lysosome-dependent pathways as a unifying theme in Parkinson's disease. Mov Disord 27:1364-1369.
141. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L. 1995. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339.
142. Tønnesen J, Parish CL, Sørensen AT, Andersson A, Lundberg C, Deisseroth K, Arenas E, Lindvall O, Kokaia M. 2011. Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson model. PLoS ONE 6:e17560.
143. Vazey EM, Aston-Jones G. 2013. New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's disease. Brain Res 1511:153-163.
144. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M. 2010. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463:1035-1041.
145. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM-Y. 2011. Exogenous a-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:57-71.
146. Wang H-D, Deutch AY. 2008. Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology 33:1276-1286.
147. Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell JC, Brown R, Gustavii B, Hagell P, Jahanshahi M, Sawle G, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. 1997. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42:95-107.
148. Wernig M, Zhao J-P, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R. 2008. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 105:5856-5861.
149. Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, Björklund A, Lindvall O, Langston JW. 1992. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 327:1556-1563.
150. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA. 2009. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132:2958-2969.
151. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung H-K, Nagy A. 2009. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458:766-770.
152. Yarnall A, Rochester L, Burn DJ. 2011. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov Disord 26:2496-2503.
153. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920.
154. Zhang Z, Li X, Xie W-J, Tuo H, Hintermann S, Jankovic J, Le W. 2012. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol Disord Drug Targets 11:768-773.